A BioPharma Dive analysis identified 31 drugmakers at a high risk of going bankrupt in the next 12 months.
The analysis used data from CreditRiskMonitor, a firm that calculates the probability that a company will go bankrupt using a scale called a FRISK score. The score is based on factors such as credit agency ratings, crowdsourced subscriber data, stock volatility and financial ratios.
The FRISK score is on a scale of 1 to 10 with 1 being the highest risk for bankruptcy and 10 being the lowest. The typical drugmaker has a FRISK score of 7, according to BioPharma Dive.
According to CreditRiskMonitor, FRISK scores have been 96 percent accurate in predicting bankruptcy.
The following list includes drugmakers traded on major U.S. exchanges with current share prices above $1 and market values above $50 million. The market values and percent stock change are current through Nov. 16.
Drugmakers with a FRISK score of 1:
- Amneal Pharmaceuticals
- Akorn
- Sorrento Therapeutics
- BioCryst Pharmaceuticals
- Novavax
Drugmakers with a FRISK score of 2: - Endo International
- Agenus
- Clovis Oncology
- AMAG Pharmaceuticals
- Puma Biotechnology
- MannKind
- Mallinckrodt
- La Jolla Pharmaceutical
- Aquestive Therapeutics
- T2 Biosystems
- Acorda Therapeutics
- Assertio Therapeutics
- Verastem
Drugmakers with a FRISK score of 3: - Teva Pharmaceutical
- Bausch Health
- ImmunoGen
- Seres Therapeutics
- CytomX Therapeutics
- Avadel Pharmaceuticals
- Correvio Pharma
- Paratek Pharmaceuticals
- vTv Therapeutics
- Adaptimmune Therapeutics
- Neos Therapeutics
- Aclaris Therapeutics
- Selecta Biosciences